Automated Large-Scale Production of Endothelial Cells

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$99,840.00
Award Year:
2003
Program:
SBIR
Phase:
Phase I
Contract:
1R43HL074681-01
Award Id:
65703
Agency Tracking Number:
HL074681
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
AASTROM BIOSCIENCES, INC., BOX 376, ANN ARBOR, MI, 48105
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
KRISTIN GOLTRY
() -
Business Contact:
JULIE CAUDILL
(734) 930-5555
JCAUDILL@AASTROM.COM
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Treatment of ischemia by administration of bone marrow (BM)-derived endothelial progenitor cells (EPC) or ex vivo expanded EPC populations has been shown to enhance vascular regeneration in animal models and in clinical trials. For cell therapy to be practical in a clinical setting, simple, efficient, GMP compliant methods for cell production are needed. Aastrom has previously developed a single-pass perfusion (SPP) bioreactor technology, the AastromReplicell TM Cell Production System (ARS), designed for automated expansion of primary human cells for clinical use. In previous studies, SPP technology has been shown to enhance function and overall production of several cell types. Based on this technology, we will develop a GMP I compliant method for the ex vivo production of substantial numbers of EPC from a small volume of BM for use in cell therapy applications. First, we will identify and optimize EPC cell culture parameters in our small-scale SPP culture system. Parameters to be examined will include starting cell population, medium serum concentration, culture duration, starting cell density and frequency of medium exchange. EPC will be enumerated and output analyzed by immunostaining and in vitro assays. Optimal culture conditions from Aim 1 will be evaluated in an in vivo model for hind limb ischemia in Aim 2. Concurrently, we will begin studies in Aim 3 to develop the EPC culture process(es) in the clinical-scale ARS. Based on small-scale results, potential revisions to the current ARS platform technology will include cell bed surface modifications and software updates to accommodate optimized medium perfusion rates. These modifications will be made with the help of in-house engineers and product specialists. Cell output from the ARS will be compared to cell output from small-scale cultures. With the successful completion of Phase I studies, a Phase II program will involve continued culture optimization and in vivo evaluations of the expanded cell products in both small-scale and clinical-scale cultures to optimize the ARS for large-scale clinical trial commercialization. Once the ARS process is established, a clinical trial will be initiated for the treatment of vascular disease. Studies will also be initiated to develop EPC gene transfer protocols within the context of the ARS platform. This work will result in the manufacture of a cell therapy kit offering automated GMP production of functional EPC cells for use in treatment of peripheral and cardiovascular diseases.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government